ChromaDex (CDXC Quick QuoteCDXC - Free Report) shares soared 12% in the last trading session to close at $10.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 92.8% gain over the past four weeks.

The company's key marketed products, Tru Niagen and Niagen, have shown promising growth in the first nine months of 2020. Moreover, with dimisnishing impact of COVID-19 following availability of vaccines, prospect of these products are likely to get boosted.

Price and Consensus

This natural products company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $15.4 million, up 17.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For ChromaDex, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CDXC going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>